KYMR - NASDAQ

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMRยทNASDAQ

$73.25

+0.77%
HealthcareBiotechnology

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$6.03B
EPS-3.6900
P/E Ratio-19.85
Earnings Date08/10/2026
Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. Fair Value Envelope

KYMR ยท NASDAQ

Our analysis suggests that KYMR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $73.25, this represents a potential HIDDEN relative to our calculated worth for Kymera Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $73.25

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$854.0M
+ Cash & Equivalents$357.0M
Firm Value-$497.0M
- Debt$82.3M
Equity Value-$579.3M
/ Shares Outstanding71,949,027B
DCF Value-$8
OVERVALUED BY 111%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$202.6M
-$176.2M
-$153.2M
-$133.3M
-$115.9M
-$100.8M
-$87.7M
-$76.3M
-$66.3M
-$57.7M
Maintenance CapEx
-$252.1K
-$219.2K
-$190.7K
-$165.9K
-$144.3K
-$125.5K
-$109.1K
-$94.9K
-$82.6K
-$71.8K
Owner Earnings
-$202.8M
-$176.4M
-$153.4M
-$133.4M
-$116.1M
-$101.0M
-$87.8M
-$76.4M
-$66.4M
-$57.8M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$187.8M
-$151.2M
-$121.8M
-$98.1M
-$79.0M
-$63.6M
-$51.2M
-$41.3M
-$33.2M
-$26.8M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your KYMR research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.